2.3.1.78: heparan-alpha-glucosaminide N-acetyltransferase
This is an abbreviated version!
For detailed information about heparan-alpha-glucosaminide N-acetyltransferase, go to the full flat file.
Word Map on EC 2.3.1.78
-
2.3.1.78
-
lysosomal
-
mucopolysaccharidosis
-
sanfilippo
-
glycosaminoglycans
-
naglu
-
alpha-n-acetylglucosaminidase
-
medicine
-
sulfamidase
-
n-acetylglucosamine-6-sulfatase
-
splice-site
-
facies
-
nonsyndromic
-
pigmentosa
-
analysis
- 2.3.1.78
- lysosomal
- mucopolysaccharidosis
-
sanfilippo
- glycosaminoglycans
- naglu
- alpha-n-acetylglucosaminidase
- medicine
-
sulfamidase
- n-acetylglucosamine-6-sulfatase
-
splice-site
-
facies
-
nonsyndromic
- pigmentosa
- analysis
Reaction
Synonyms
acetyl-CoA:alpha-glucosaminide N-acetyltransferase, acetyl-coenzyme A-alpha-glucosaminide N-acetyltransferase, acetyl-coenzyme A:alpha-glucosaminide N-acetyltransferase, acetyl-coenzyme:alpha-D-2-amino-glucosamine transferase, acetyltransferase, alpha-glucosaminide, acetyl–coenzyme A:alpha-glucosaminide N-acetyltransferase, GNAT, heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase, heparan sulfate acetyl-CoA:alpha-glucosaminide N-acetyltransferase, HGSNAT, TMEM76, transmembrane protein 76
ECTree
Advanced search results
Application
Application on EC 2.3.1.78 - heparan-alpha-glucosaminide N-acetyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
medicine
direct method to assay HGSNAT enzymatic activity using fluorescent BODIPY-glucosamine, i.e. 1-[4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl-glycylamino]-beta-D-glucosamine, as a substrate
analysis
direct method to assay HGSNAT enzymatic activity using fluorescent BODIPY-glucosamine as a substrate. The assay is specific and potentially applicable for the biochemical diagnosis of mucopolysaccharidosis III type and high-throughput screening for HGSNAT inhibitors
-
overview, design and synthesis of substrate and internal standard conjugates as substrates in enzyme assay for confirmation of enzyme deficiency using a combination of affinity chromatography and electrospray ionization mass spectrometry
medicine
-
mucopolysaccharidosis type IIIC or Sanfilippo syndrome type C is an autosomal recessive disorder caused by deficiency of heparan sulfate acetyl-CoA:alpha-glucosaminide N-acetyltransferase
medicine
direct method to assay HGSNAT enzymatic activity using fluorescent BODIPY-glucosamine, i.e. 1-[4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl-glycylamino]-beta-D-glucosamine, as a substrate. Cultured fibroblasts of mucopolysaccharidosis III type C patients show a profound deficiency of HGSNAT activity as compared to normal controls as well as to mucopolysaccharidosis III type A and D patients known to have normal HGSNAT activity
medicine
identification of HGSNAT mutations in six patients with non-syndromic retinitis pigmentosa. Homozygous HGSNAT variant c.370A>T leads to partial skipping of exon 3. In other patients with retinitis pigmentosa, a complex HGSNAT variant, c.[398G>C; 1843G>A] on one allele, and c.1843G>A on the other allele, is found. HGSNAT activity levels in blood leukocytes of patients are reduced compared with healthy controls, but usually higher than those in mucopolysaccharidosis type IIIC patients. All patients are diagnosed with non-syndromic retinitis pigmentosa and do not exhibit neurological deterioration, or any phenotypic features consistent with in mucopolysaccharidosis type IIIC. Four of the patients are over 60 years old, exceeding by far the life expectancy of mucopolysaccharidosis IIIC patients